Just Published: Adjuvant pembrolizumab after resected stage III melanoma led to a 5-year recurrence-free survival of 55.4%, compared with 38.3% in patients treated with placebo. Read more in NEJM Evidence: https://eviden.cc/3x6Wg6l #ESMO22 | The New England Journal of Medicine

Patients with stage III or IV melanoma can benefit from adjuvant pembrolizumab. Whether outcomes with neoadjuvant plus adjuvant pembrolizumab would be better than those with adjuvant therapy alone is unknown. New research findings are summarized in a short video. https://nej.md/3YaD6qN | The New England Journal of Medicine